Kornimate/medical-research-clean huggingface dataset:
jena sepsis registry

Conditions: Severe Sepsis or Septic Shock (ICD-10-GM, R65.0, R65.1)

Summary: despite the burden of severe sepsis and septic shock deficiencies in the quality of sepsis management are recognized. investigators present a population-based registry with easy feasibility as part of german center for sepsis control \& care (cscc). all icu patients of the jena university hospital, germany will be screened for inclusion (severe sepsis or septic shock). baseline data on icu- and hospital care will be extracted from patient records at icu discharge. the primary outcome is change in all-cause mortality from baseline to follow up at 6, 12, 24, 36, 48 and 60 months after diagnosis of sepsis. follow-up data will be collected from the primary care provider of the patient. the registry may provide valid data on quality in sepsis care.


Eligibility criteria:
inclusion criteria: * patients treated in one of the icus will be enrolled if they were 18 years or older and fulfill the diagnostic criteria of severe sepsis or septic shock (icd-10-gm, r65.0, r65.1) (19), (20). * diagnosis of severe sepsis or septic shock requires the following criteria: a microbiologically documented and/or clinically evident infection, at least two of the four criteria of the systemic inflammatory response syndrome (sirs) and at least one new organ dysfunction, remote from the site of infection. exclusion criteria: -
effectiveness of single doses of ibuprofen in patients with osteoarthritis of the knee

Conditions: Osteoarthritis

Summary: to demonstrate that new drugs work, many complex multidose studies are often required. the intent of this study is to use ibuprofen as an example of a marketed pain relief drug to validate a simpler single dose model for future assessment of new pain drugs.


Eligibility criteria:
inclusion criteria: * subjects diagnosed with primary osteoarthritis of the knee. * have at least 3 months in symptom duration prior to screening visit. * regular user of a prescribed non-steroidal anti-inflammatory drug (nsaid) or selective cyclo-oxygenase ii (cox2) inhibitor for management of knee pain. * pain walking on flat surface within specific interval prior to study start. exclusion criteria: * history of hypersensitivity to nsaids. * allergy to ibuprofen. * use of assistive devices other than a cane or knee brace. * history of specified diseases/illnesses. * abnormal blood tests pre-study.

Keywords: osteoarthritis ibuprofen cox2 vas knee single dose
study of hla-haploidentical stem cell transplantation to treat clinically aggressive sickle cell disease

Conditions: Sickle Cell Disease

Summary: the study is a phase ii clinical trial. patients will receive intensity modulated total body irradiation (tbi) at a dose of 3 gy with standard fludarabine/ i.v. cyclophosphamide conditioning prior to human leukocyte antigen (hla)-haploidentical hematopoietic stem cell transplant (hsct). the primary objective of the study is to determine the engraftment at day +60 following hla-haploidentical hematopoietic stem cell transplant protocol using immunosuppressive agents and low-dose total body irradiation (tbi) for conditioning and post-transplant cyclophosphamide in patients with sickle cell disease.


Eligibility criteria:
patient eligibility: 1. patients with sickle cell disease are eligible if they have any of the following complications: 1.1 stroke or central nervous system event lasting longer than 24 hours 1.2 frequent vaso-occlusive pain episodes, defined as ≥ 3 per year requiring emergency room, acute care center, hospital admissions, or home bedrest leading to absence from work or school. 1.3 recurrent episodes of priapism, defined as ≥ 2 per year requiring emergency room visits 1.4 acute chest syndrome with recurrent hospitalizations, defined as ≥ 2 lifetime events 1.5 red-cell alloimmunization (≥ 2 antibodies) during long-term transfusion therapy 1.6 bilateral proliferative retinopathy with major visual impairment in at least one eye 1.7 osteonecrosis of 2 or more joints 1.8 sickle cell nephropathy, defined by a gfr \ 300 mg/g creatinine) 1.9 pulmonary hypertension, defined by a mean pulmonary arterypressure \>25mmhg 2. age 16-60 years 3. karnofsky performance status of 60 or higher (appendix a) 4. adequate cardiac function, defined as left ventricular ejection fraction ≥ 40% 5. adequate pulmonary function, defined as diffusion lung capacity of carbon monoxide ≥ 50% predicted (after adjustment for hemoglobin concentration) 6. estimated gfr ≥ 50ml/min/1.73m2 as calculated by the modified mdrd equation 7. alt ≤ 3x upper limit of normal 8. hiv-negative 9. patient is not pregnant 10. patient is able and willing to sign informed consent 11. patient does not have a fully hla-matched sibling donor 12. patient has an hla-haploidentical relative donor eligibility relatives (parents, offspring, siblings, aunts/uncles, cousins) will be tested by molecular typing of hla class i (a, b, and c) and class ii (drb1) at low resolution. only those that are an hla-haploidentical match (≥ 4/8) will be considered as a potential donor. note: if during testing, a fully hla-matched sibling donor is found and is willing to donate his/her stem cells, the potential subject will not be eligible for this protocol. donor consent will be obtained as per standard protocol of the bone marrow transplant unit.
comparison of thrust manipulation of sacroiliac joint and pelvic stabilization exercises in post partum low back pain

Conditions: Low Back Pain, Post Partum

Summary: compare the effectiveness of si joint thrust manipulation and pelvic stabilization exercises on modified oswestry low back pain index (odi) and numeric pain rating scale (nprs) in patients with post-partum lower back pain.

patients fulfilling the inclusion criteria will be divided into 2 groups i.e. group a and group b. patients in group a will receive thrust manipulation technique and group b will receive pelvic stabilization exercises, heating pad will be given to both groups. patients will be treated 3 times per week for 4 consecutive weeks. patient will be evaluated at baseline, midline and at end of 4th week. pain, functional status and disability will be evaluated after every 3 sessions.

Eligibility criteria:
inclusion criteria: * age 20-40 years * postpartum women (after 6 weeks)(3, 12) * postpartum lbp patient * patient pain increased by provocation test i.e. faber test, high thrust test and gaenslen test exclusion criteria: * c-section * inflammatory or malignant type of pain * neurological deficit * severe trauma * pelvic fracture * osteoporosis, spinal stenosis, spondylolysis, spondoloesthesisi
high versus standard dose of proton pump inhibitors (ppis) in peptic ulcer bleeding

Conditions: Peptic Ulcers; Upper Gastrointestinal Bleeding

Summary: high intravenous dosage of proton pump inhibitors is not better than standard dosage in bleeding peptic ulcers successfully treated by endoscopic therapy

the recent canadian consensus conference on the management of patients with non-variceal upper gastrointestinal bleeding recommends a high regimen of ppis, consisting in a dosage of 80-mg bolus followed by the 8 mg/h infusion, as being superior to the standard dosage (40 mg twice daily by bolus injection) in conjunction with some type of endoscopic therapy. however, by pooling data fromm studies comparing high doses of ppis as continuous infusion versus regular doses as intermittent bolus, rebleeding, surgery, and mortality were not significantly different. as the previous conclusion became apparent in a meta-analytical evaluation of only 2 randomized clinical trials, more studies are needed on this topic.

Eligibility criteria:
inclusion criteria: * consecutive patients admitted for upper gastrointestinal bleeding secondary to peptic ulcers that have been successfully treated with endoscopic therapy exclusion criteria: * variceal esophageal bleeding * concurrent ppi use * moribund patients

Keywords: ppis, endoscopic therapy, peptic ulcers, upper gastrointestinal bleeding, non-variceal upper gastrointestinal bleeding
deep learning model to predict the recurrence of stage ia invasive lung adenocarcinoma after sub-lobar resection

Conditions: Focus on Developing a Deep Learning Model to Predict the Recurrence Risk of Stage IA Invasive Lung Adenocarcinoma After Sub-lobar Resection

Summary: this study aims to develop a deep learning model based on noncontrast ct images to predict the recurrence risk of stage ia invasive lung adenocarcinoma after sub-lobar resection，which can serve as potential tool to assist thoracic surgeons in making optimal treatment decisions.the study will use existing ct data to train and validate the model, without requiring any additional intervention for the participants.

this study is designed to develop a deep learning model to predict the recurrence risk of stage ia invasive lung adenocarcinoma after sub-lobar resection using noncontrast ct images. the best indications for sub-lobar resection in patients with early-stage ladc are still debated, making surgical method selection somewhat difficult. the deep learning model can noninvasively and objectively predict the recurrence risk of patients with stage ia iladc following sub-lobectomy and are helpful in predicting prognosis of patients with stage ia iladc after sub-lobectomy and can facilitate the choosing of the optimal surgery mode of these patients. the study will utilize retrospective data from patients with stage ia invasive lung adenocarcinoma after sub-lobar resection . noncontrast ct images will be collected at admission and used as inputs for the deep learning model. the model will be trained using convolutional neural networks (cnn) to identify patterns associated with recurrence. in addition to model development, the study will also evaluate the model's performance on a separate validation cohort to assess generalizability. statistical analyses will include performance metrics such as area under the receiver operating characteristic (roc) curve (auc) and precision-recall curve. this study aims to provide a valuable tool for clinicians to make timely decisions in choosing the optimal therapeutic approach.

Eligibility criteria:
inclusion criteria:(i) pathological confirmation of ladc; (ii) undergoing sub-lobar resection (wedge resection or segmentectomy); (iii) ct scanning prior to surgery; (iv) pathological staging of ia; and (v) complete clinical and follow-up data. - exclusion criteria:(i) multiple primary ladc; and (ii) other pulmonary lesions that might interfere with the morphological assessment of tumors. -

Keywords: lung cancer sub-lobar resection computed tomography deep learning
efficacy and tolerability of azarga® as replacement therapy in patients on combigan® therapy in canada

Conditions: Glaucoma; Ocular Hypertension; Open-angle Glaucoma

Summary: the purpose of this study was to assess the efficacy and tolerability of changing to azarga® from prior brimonidine 0.2%/timolol 0.5% fixed combination (combigan®) therapy in patients with open-angle glaucoma or ocular hypertension and uncontrolled intraocular pressure (iop).


Eligibility criteria:
inclusion criteria: * willing to sign an informed consent form. * clinical diagnosis of ocular hypertension, exfoliative open-angle or pigment dispersion glaucoma in at least one eye (study eye). * be on a stable iop lowering regimen within 30 days of screening visit. * iop considered to be safe, in both eyes, in such a way that should assure clinical stability of vision and the optic nerve throughout the study period. * willing to discontinue the use of combigan® prior to receiving the study drug at visit 1. * iop of between 19 and 35 mmhg in at least one eye (which would be the study eye) while on brimonidine/timolol fixed combination therapy. * best corrected visual acuity of 6/60 (20/200 snellen, 1.0 logmar) or better in each eye. * willing to follow instructions and able to attend required study visits. * other protocol-defined inclusion criteria may apply. exclusion criteria: * known history of hypersensitivity to any component of the preparations used in this study. * presence of primary or secondary glaucoma not listed in inclusion criterion #2. * history of ocular herpes simplex. * abnormality preventing reliable applanation tonometry. * corneal dystrophies. * concurrent infectious/noninfectious conjunctivitis, keratitis or uveitis in either eye. blepharitis or non-clinically significant conjunctival injection is allowed. * intraocular conventional surgery or laser surgery in study eye(s) less than 3 months prior to the screening visit. * risk of visual field or visual acuity worsening as a consequence of participation in the study, in the investigator's best judgment. * progressive retinal or optic nerve disease from any cause. * women of childbearing potential not using reliable means of birth control for at least 1 month prior to the screening/baseline visit. * pregnant or lactating. * other protocol-defined exclusion criteria may apply.

Keywords: glaucoma ocular hypertension intraocular pressure (iop) open angle glaucoma pigment dispersion glaucoma pigmentary
covid-19 pandemic and use of video laryngoscopy

Conditions: COVID-19 Pneumonia

Summary: severe acute respiratory syndrome coronavirus 2 (sars-cov-2) causes a highly contagious infection with the highest viral load in the upper respiratory secretions. despite using personal protective equipment, sars-cov-2 contamination to the healthcare personnel is possible during the airway management of infected patients. direct laryngoscopy remains as the most common method for endotracheal intubation. our study aimed to compare the use of video laryngoscopy with direct laryngoscopy for tracheal intubation in adult patients receiving general anesthesia for elective surgery during the covid-19 pandemic.


Eligibility criteria:
inclusion criteria: * asa i-ii * elective surgery exclusion criteria: * intraoral or neck surgery * gastroesophageal reflux * delayed gastric emptying * pregnancy * scoliosis
study of blood immune cells in cancer patients compared to controls

Conditions: Solid Carcinoma

Summary: tumors have a systemic immune modifying effect. they affect the immune system similarly to states of chronic inflammation and these effects can: * be monitored through analysis of nk t and myeloid cells mainly through studies of the zeta chain but also through other means * may be decreased following effective anticancer therapy - may even be used to study the effectiveness of anticancer therapy * are important to monitor if the investigators plan on formulation of systemic immune therapy thus immumonitoring of systemic blood cells may turn out to be an important prognostic and predictive factor in many cancer types

cd247 known also as the zeta chain is important for relaying t-cell induced signal transduction. interestingly studies by baniash and others have demonstrated that this chain is down regulated in states of chronic inflammation and cancer in peripheral blood t cells and also in nk cells however there has not been a prospective study of this marker in cancer and control patients such a study will reveal not only the levels of cd247 in immune cells of cancer patients compared to controls but may reveal the effect of anticancer therapies on cd247 in cancer patients such a study may contribute significantly to our ability to monitor systemic immune system characteristics in cancer patients and help in any further studies of immunomodulation such as vaccination schemes in such patients

Eligibility criteria:
inclusion criteria: * patients with cancer or blood donators agreeing to participate in the trial exclusion criteria: * other disease states which may cause chronic inflammation

Keywords: cancer immunomonitoring cd247 -zeta chain chronic inflamation anticancertherapy
physiotherapy management in women with urinary incontinence

Conditions: Urinary Incontinence

Summary: main objective: the primary aim of the study is to assess whether the author's exercise programme has an effect on reducing urinary incontinence and pelvic floor dysfunction after childbirth, considering vacuum extractor, forceps and caesarean section deliveries. secondary objective: the secondary objective is to determine whether the duration of the author's exercise programme is sufficient to achieve positive changes in women.

the study will involve women with stress urinary incontinence, urge urinary incontinence, and mixed urinary incontinence. participants will be women aged 20-80 years (meeting inclusion criteria: urinary incontinence, regular menstrual cycles, pre-and post menopausal period, natural childbirth or cesarean section, and deliveries using forceps and vacuum extractors; exclusion criteria: no urinary incontinence, irregular menstrual cycles, no childbirth, abdominal surgeries/procedures, active cancer, no gynecological check-up in the last 12 months, recurrent urogenital infections, joint hypermobility). a total of 300 women will be examined, including 100 women meeting the inclusion criteria, 100 women meeting the inclusion criteria but not interested in exercising, and 100 healthy women. participants can withdraw from the study at any stage.study group division based on the evaluation of posture type, pelvic pattern, and postural stability, participants will be divided into three groups: 1. women meeting inclusion criteria performing the author's exercise program - experimental group. 2. women meeting inclusion criteria but not interested in performing the author's exercise program - control group. 3. healthy women - control group. the experimental group will perform the author's pelvic floor muscle exercise program daily for six weeks, at a fixed time each day, under weekly physiotherapist supervision and independently on other days (after proper instruction by the physiotherapist).

Eligibility criteria:
inclusion criteria: * urinary incontinence * regular menstrual cycles * pre and post-menopausal period * natural childbirth or cesarean section * deliveries using forceps and vacuum extractors exclusion criteria: * no urinary incontinence * irregular menstrual cycles * no childbirth * abdominal surgeries/procedures active cancer no gynecological check-up in the last 12 months recurrent urogenital infections joint hypermobility contorl group will be healthy women

Keywords: the author's exercise program urinary incontinence physiotherapy
aprepitant to mitigate opioids' cognitive side effects

Conditions: Cognitive Dysfunction

Summary: morphine and similar substances (called opioids) are often prescribed for moderate to severe pain, such as after a surgery, thus allowing for minimal pain and a better recovery. unfortunately various, non-dangerous side effects from opioids occur often that limit the way patients feel and can take of themselves, despite otherwise good pain control and minimal limitations from the surgery itself.

in this proposed study the investigators want to examine if the drug aprepitant can decrease the so called "cognitive impairments" opioids may cause, such as drowsiness, loopiness and feeling "high". this would allow for a better recovery period, in which patients can be more "themselves", participate in activities around them and move forward. subjects scheduled for elective surgeries with expected opioid medication for moderate to severe pain and good functional status shortly after surgery will be randomized to receive either aprepitant or placebo shortly before their surgery and for two more days thereafter. a telephone interview for cognitive status and several specific questions will be used to assess the effect of aprepitant on the subjects' cognitive and functional status.

Eligibility criteria:
inclusion criteria: * healthy english speaking, opioid-naive consenting adults exclusion criteria: * current or very recent (\< 3 months) opioid therapy * morbid obesity * liver disease * therapy with pimozide, terfenadine, astemizole, cisapride, vitamin k antagonists (warfarin), hormonal contraceptives * acute or chronic infections * immunocompromised status * hemodynamically unstable, hemorrhage (bleeding) * recent surgery * pregnancy, nursing * younger than 18 years old * not proficient of the english language

Keywords: drowsiness loopiness nausea
tacrolimus/methotrexate versus cyclosporine/methotrexate for prophylaxis of graft versus host disease

Conditions: Graft vs Host Disease

Summary: this study aims to compare efficacy and safety of tacrolimus/methotrexate with cyclosporine/methotrexate for graft versus host disease prophylaxis in paediatric allogeneic hematopoietic stem cell transplantation patients.


Eligibility criteria:
inclusion criteria: * diagnosis of hematological malignancy * age under 18 years old * serum bilirubin less than 1.5 x upper limit of normal * aspartate transaminase, alanine transaminase less than 2.5 x upper limit of normal * alkaline phosphatase less than 2.5 x upper limit of normal * serum creatinine less than 1.5 x upper limit of normal * agrees to participate, and informed consent signed exclusion criteria: * evidence of hiv infection * documented uncontrolled disease (infections) * prior transplantation (hematopoietic stem cell or solid organs)
comparison of the effectiveness of sambiloto herbs (andrographis paniculata) and brisk walking exercise on blood glucose of obese patients

Conditions: MeSH

Summary: problem formulation 1. does herbal medicine sambiloto affect the blood glucose levels of obese sufferers? 2. does brisk walking affect blood glucose levels in obese sufferers? 3. does the combination of bitter herbal medicine and brisk walking have an effect on blood glucose levels in obese sufferers? 4. is there a difference in the effectiveness between herbal bitter and brisk walking and the combination on blood glucose levels in obese sufferers? research objectives general objectives : the general aim of this research is to determine the difference in effectiveness between the herbal medicine sambiloto and brisk walking as well as the combination on the blood glucose levels of obese sufferers. specific objective : 1. knowing the effect of herbal medicine sambiloto on blood glucose in obese sufferers. 2. knowing the effect of brisk walking on blood glucose in obese sufferers. 3. to determine the effect of the combination of herbal medicine sambiloto and brisk walking on blood glucose levels in obese sufferers.

this type of research uses the quasi experimental method type non-equivalent control group design, with a research design in the form of two group pre test and post test design, in this study there are two groups that will be measured pretest before intervention and post test after intervention and 1 control group without being given intervention. the intervention group is divided into two groups, namely the group given the herbal medicine sambiloto, and the group given the brisk walking exercise treatment. quasi-experimental research design with research design in the form of two group pre test and post test design.

Eligibility criteria:
inclusion criteria: 1. willing to be a respondent with informed consent 2. obesity sufferers in the jekan raya district area 3. have a bmi ≥ 25 kg/m2 (obesity i) 4. adult age (19-39 years) exclusion criteria: 1. not being present or out of town during the research 2. unable to continue research due to serious illness or death 3. withdraw while participating in the research 4. have a history of drug allergies 5. experiencing decreased consciousness 6. experiencing an extremity injury 7. have a history of cardiovascular disease, kidney disease or stomach ulcers 8. have a history of bloody stools 9. are pregnant or breastfeeding

Keywords: obese